MC2 Therapeutics
A commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions initially focusing on manifestations in the skin.
Its approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking. Fuelled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with immune-mediated and inflammatory conditions.
Latest MC2 Therapeutics News & Features
25 September 2023
31 August 2023
17 February 2021
22 July 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze